Table 1 Characteristic stratified by hepatic inflammation

Gender (male, %)

43 (86.0)

226 (82.5)

269 (85.7)

0.538

Age, y

50.00 [40.25, 60.50]

50.00 [45.00, 58.75]

51.00 [45.00, 60.00]

0.642

AFP (> 400 ng/mL, %)

16 (32.0)

112 (40.9)

134 (42.7)

0.361

HBeAg (%)

13 (26.0)

41 (15.0)

80 (25.5)

0.005

Tumor size, cm

4.85 [3.00, 7.32]

4.05 [3.00, 7.50]

4.50 [3.00, 6.80]

0.995

Multiple tumor (%)

1 (2.0)

2 (0.7)

9 (2.9)

0.163

Poorly differentiation, (%)

25 (50.0)

124 (45.3)

151 (48.1)

0.717

Hepatic fibrosis

< 0.001

  minor

18 (36.0)

84 (30.7)

23 (7.3)

  advanced

12 (24.0)

62 (22.6)

76 (24.2)

  cirrhosis

20 (40.0)

128 (46.7)

215 (68.5)

MVI, (%)

8 (16.0)

69 (25.2)

92 (29.3)

0.114

Satellite, (%)

2 (4.0)

21 (7.7)

37 (11.8)

0.092

Fatty liver, (%)

12 (24.0)

52 (19.0)

80 (25.5)

0.165

Capsule invasion, (%)

26 (52.0)

124 (45.3)

118 (37.6)

0.056

HBV-DNA, (> 2000 IU/mL, %)

19 (38.0)

130 (47.4)

190 (60.5)

0.001

PT, s

12.10 [11.70, 12.50]

12.10 [11.50, 12.90]

12.10 [11.60, 12.88]

0.881

INR

1.00 [1.00, 1.10]

1.00 [1.00, 1.10]

1.00 [1.00, 1.10]

0.773

RBC, x10⁹/L

4.65 [4.26, 5.16]

4.74 [4.30, 5.04]

4.73 [4.35, 5.10]

0.661

HB, g/L

144.50 [125.50, 154.00]

145.00 [132.00, 155.00]

147.00 [136.00, 155.75]

0.127

PLR(> 101, %)

14 (28.0)

122 (44.5)

110 (35.0)

0.017

NLR(> 2.6, %)

15 (30.0)

94 (34.3)

95 (30.3)

0.548

ALT(> 40 IU/L, %)

16 (32.0)

100 (36.5)

146 (46.5)

0.019

AST(> 40 IU/L, %)

21 (42.0)

92 (33.6)

132 (42.0)

0.094

ALB(≤ 40 g/L, %)

1 (2.0)

7 (2.6)

14 (4.5)

0.38

TBIL(> 28 umol/L, %)

2 (4.0)

5 (1.8)

12 (3.8)

0.33

PLT(≤ 100 × 10⁹/L, %)

17 (34.0)

66 (24.1)

107 (34.1)

0.024

FIB-4(> 3.6, %)

17 (34.0)

66 (24.1)

97 (30.9)

0.12